An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a small abdominal aortic aneurysm and mild to moderate hypertension on aneurysmal FDG-uptake as measured with FDG PET.

Trial Profile

An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a small abdominal aortic aneurysm and mild to moderate hypertension on aneurysmal FDG-uptake as measured with FDG PET.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms PISA
  • Most Recent Events

    • 08 Dec 2014 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 31 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01425242).
    • 26 Aug 2011 Planned end date changed from 14 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top